Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | UBE2N | P61088 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | LIPE | Q05469 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5225924 | 0.89 | TAS2R14 (0.40) | ALDH1A1LMNATAS2R14 | |
| SCHEMBL5435181 | 0.87 | TAS2R14 (0.39) | ALDH1A1SMN1; SMN2TAS2R14 | |
| SCHEMBL5224874 | 0.85 | ALDH1A1 (0.52) | ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL4671174 | 0.78 | SMN1; SMN2 (0.51) | ALDH1A1LMNASMN1; SMN2HTTATM | |
| SCHEMBL5228366 | 0.76 | PPARG (0.51) | ALDH1A1LMNAMAPTSMN1; SMN2 | |
| SCHEMBL5225058 | 0.75 | ALDH1A1 (0.54) | ALDH1A1LMNASMN1; SMN2HTT | |
| SCHEMBL5434168 | 0.73 | ALDH1A1 (0.53) | ALDH1A1LMNAMAPTSMN1; SMN2HTT | |
| SCHEMBL2513385 | 0.70 | TAS2R14 (0.70) | ALDH1A1TAS2R14 | |
| SCHEMBL7358861 | 0.68 | LMNA (0.60) | ALDH1A1GAALMNASMN1; SMN2LIPE | |
| SCHEMBL962782 | 0.66 | LMNA (0.54) | GAALMNAMAPTSMN1; SMN2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070254882-A1 | Sulfamide Derivatives and Pharmaceutical Composition for Upregulation of Lipid Metabolism Comprising Same | CRYSTAL GENOMICS, INC. (KR) | 2007-11-01 | — | — | US | disclosed |
| EP-1778654-A1 | SULFAMIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITION FOR UPREGULATION OF LIPID METABOLISM COMPRISING SAME | Crystalgenomics, Inc. (KR) | 2007-05-02 | — | — | EP | disclosed |
| WO-2006006832-A1 | SULFAMIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITION FOR UPREGULATION OF LIPID METABOLISM COMPRISING SAME | CRYSTALGENOMICS, INC. (KR) | 2006-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254882-A1 | Sulfamide Derivatives and Pharmaceutical Composition for Upregulation of Lipid Metabolism Comprising Same | SULT2A1, SPTLC2, SGMS2 | ALDH1A1 1086/4885GAA 1171/4885LMNA 4770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.